TSX runs higher on rate cut expectations
Glendon E. French III, a director at Pulmonx Corp (NASDAQ:LUNG), recently sold 20,000 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The medical device company, currently valued at $310 million, has shown strong momentum with a 13.4% return year-to-date according to InvestingPro data. The shares were sold at a weighted average price of $7.85, resulting in a total transaction value of $157,000. This sale was conducted under a Rule 10b5-1 trading plan, which French adopted on June 10, 2024. Following this transaction, French holds 991,974 shares in Pulmonx Corp. The shares were sold in multiple transactions, with prices ranging from $7.71 to $7.95. With analysts setting price targets between $8 and $17, and the stock currently trading near Fair Value, investors can access comprehensive insider trading analysis and 6 additional key insights through InvestingPro’s detailed research reports.
In other recent news, Pulmonx Corp. reported a robust fourth-quarter performance for 2024, with revenue reaching $23.8 million, marking a 23% increase year-over-year. The company also reported an earnings per share (EPS) of -$0.33, surpassing the forecasted -$0.4475. This earnings beat contributed to positive investor sentiment. Citi analysts responded by raising Pulmonx’s price target to $8.00, maintaining a Neutral rating, after the company exceeded revenue expectations and showed strong international growth.
Additionally, Canaccord Genuity reaffirmed its Buy rating on Pulmonx with a $16 price target, noting the company’s ambitious growth initiatives and strategic plans to reach cash flow profitability. Boral (OTC:BOALY) Capital also initiated coverage with a Buy rating and a $17 price target, citing Pulmonx’s innovative treatments and potential for market expansion. Pulmonx’s management emphasized the company’s focus on expanding physician adoption and international presence, projecting 2025 revenue between $96 million and $98 million, representing a growth of 16%-18%.
These recent developments highlight Pulmonx’s strategic focus on innovation and market expansion, as well as the positive outlook from multiple analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.